Search
MSK’s Supportive Care Service aims to improve quality of life for all people with cancer.
Degrees were presented and awards were given at the 39th annual ceremony, held on May 30.
Even the most common cancers have aspects that are not fully grasped by the public.
Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.
The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.
美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物也称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).
Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.
Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.
The advent of hepatic arterial infusion chemotherapy (HAI) for treating patients with resectable colorectal liver metastases has increased survival outcomes to previously unimaginable levels. However, questions remain about the effectiveness of its use in patients with initially unresectable colorectal liver metastases.